Could a daily cannabinoid pill tame tourette tics?
NCT ID NCT05126888
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a daily oral medication called SCI-110, made from cannabinoids, to see if it can safely reduce tics in adults with Tourette syndrome. About 164 adults aged 18 to 65 with moderate to severe tics will receive either the drug or a placebo, then switch after 12 weeks. The main goal is to measure changes in tic severity using a standard rating scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TOURETTE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medizinische Hochschule Hannover
Hanover, 30625, Germany
-
Neurological Institute, Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Yale Child Study Center - NIHB 205
New Haven, Connecticut, 06519, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A common antidepressant may tame anxiety in kids with autism and ADHD — a trial puts it to the test
- Brain scans may reveal why behavioral therapy helps some teens with tics
- Can a dopamine-blocking drug safely control tourette syndrome over years?
- Mapping tic patterns could lead to personalized therapy for tourette syndrome
- Sound waves aimed at the brain could quiet tics without surgery
- Wrist zap may tame tics: electrical pulses tested as Drug-Free option